Alison J. Carey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alison J. Carey has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Ogan Kartal Kumova
Drexel University College of Medicine Department of Microbiology and Immunology Philadelphia, PA 19102
7 shared publications - Peter D. Katsikis
Department of Immunology, Erasmus University Medical Center, Rotterdam, Netherlands
5 shared publications - Jennifer L. Hope
Immune Cell Regulation and Targeting Program, Sidney Kimmel Comprehensive Cancer Center, Philadelphia, Pennsylvania
4 shared publications Ogan K. Kumova
Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States
4 shared publications- Yvonne M. Mueller
Department of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands
4 shared publications - Abigail Patricia Onufer
Department of Microbiology and Immunology, Drexel University College of Medicine , Philadelphia, PA
3 shared publications
Latest Publications
- 27 April 2026
- Published by Drexel University Libraries
The differential roles of Type I and Type III interferon signaling in the neonatal response to influenza virus infection
Infants are remarkably susceptible to influenza virus (IV) infections. Type I and type III interferons (IFN-Is and IFN-IIIs) are key components of the innate immune response required for protection in adults. In contrast, using a neonatal murine model of IV infection, our lab has recently shown that IFN-IIIs are the dominant IFN driving neonatal protection, while IFN-Is exacerbated mortality. However, the mechanisms underlying these differential influences are unknown. In the delicate neonatal lung, we hypothesized that IFN-Is and IFN-IIIs exert opposing effects on epithelial and immune cell communication. This relationship is crucial for balancing viral clearance with tissue protection. Using bulk-RNAseq we revealed that IFN-Is inhibited early repair programs within IV-infected neonatal type II epithelial cells, which decreased lung repair and tight junction expression in the whole lung late in infection. To further elucidate the impact IFN-I and IFN-III signaling on epithelial and immune cell interactions, we performed spatial transcriptomics on IV-infected whole lung tissue sections from neonates with IFN signaling intact, and those lacking either IFN-I or IFN-III signaling. Here, IFN-Is induced robust inflammatory programs, alveolar barrier disruption, and neutrophil influx. Notably, loss of IFN-III signaling amplified neutrophil degranulation. When taken together, we find that IFN-I signaling inhibited lung repair, increased alveolar barrier disruption, and drove neutrophil activation in IV-infected neonates. In contrast, IFN-III signaling induced antiviral gene expression while counteracting these pathogenic effects, which supported essential development. This work provides further insight into age-specific responses to respiratory viral infections and importantly identifies therapeutic avenues for this vulnerable population.
- 27 April 2026
- Published by Drexel University Libraries
The differential roles of Type I and Type III interferon signaling in the neonatal response to influenza virus infection
Infants are remarkably susceptible to influenza virus (IV) infections. Type I and type III interferons (IFN-Is and IFN-IIIs) are key components of the innate immune response required for protection in adults. In contrast, using a neonatal murine model of IV infection, our lab has recently shown that IFN-IIIs are the dominant IFN driving neonatal protection, while IFN-Is exacerbated mortality. However, the mechanisms underlying these differential influences are unknown. In the delicate neonatal lung, we hypothesized that IFN-Is and IFN-IIIs exert opposing effects on epithelial and immune cell communication. This relationship is crucial for balancing viral clearance with tissue protection. Using bulk-RNAseq we revealed that IFN-Is inhibited early repair programs within IV-infected neonatal type II epithelial cells, which decreased lung repair and tight junction expression in the whole lung late in infection. To further elucidate the impact IFN-I and IFN-III signaling on epithelial and immune cell interactions, we performed spatial transcriptomics on IV-infected whole lung tissue sections from neonates with IFN signaling intact, and those lacking either IFN-I or IFN-III signaling. Here, IFN-Is induced robust inflammatory programs, alveolar barrier disruption, and neutrophil influx. Notably, loss of IFN-III signaling amplified neutrophil degranulation. When taken together, we find that IFN-I signaling inhibited lung repair, increased alveolar barrier disruption, and drove neutrophil activation in IV-infected neonates. In contrast, IFN-III signaling induced antiviral gene expression while counteracting these pathogenic effects, which supported essential development. This work provides further insight into age-specific responses to respiratory viral infections and importantly identifies therapeutic avenues for this vulnerable population.
- 16 March 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (10) , 1440-1450
Myeloid TLR2 signaling amplifies immunopathology in influenza-infected murine neonates
We previously demonstrated pretreatment with intranasal Lactobacillus rhammosus GG (LGG) prior to influenza viral (IAV) infection protected murine neonates through toll-like receptor (TLR) priming. Based on these results, we hypothesized neonates had impaired TLR activation in response to IAV. However, translational studies with human neonatal monocytes stimulated with IAV exhibited comparable IL-6 production, and sustained TLR2 expression compared to adults. Next, to further investigate the role of TLR2, transgenic mice lacking the TLR2 gene (TLR2-/-) were intranasally infected with IAV. TLR2-/- neonates displayed improved survival over C57BL/6 neonates after IAV infection, with reduced neutrophil recruitment at 6-days post-infection. To test the role of neutrophils in increasing mortality, neutrophil depletion was performed in C57BL/6 neonates; survival was improved. Additionally, treatment with an anti-TLR2 blocking antibody improved survival in the C57BL/6 neonates. Similarly, myeloid-specific TLR2-deficient mice demonstrated enhanced survival with improved histopathology and decreased neutrophil-associated pro-inflammatory cytokines and chemokines (IL-6, TNF-α, MCP-1, CXCL1), despite no changes in immune cell recruitment. Moreover, conditional knockout neonates did not amplify production of pro-inflammatory cytokines and chemokines from 3-days post-infection to 6-days post-infection, compared to the age-matched neonatal control group. These findings suggest that myeloid TLR2 signaling exacerbates neonatal susceptibility to respiratory viral infections by driving increased pulmonary inflammation over the first week of infection. Targeting TLR2 could represent a therapeutic strategy to protect this vulnerable population during respiratory viral infections.
- 16 March 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (10) , 1440-1450
Myeloid TLR2 signaling amplifies immunopathology in influenza-infected murine neonates
We previously demonstrated pretreatment with intranasal Lactobacillus rhammosus GG (LGG) prior to influenza viral (IAV) infection protected murine neonates through toll-like receptor (TLR) priming. Based on these results, we hypothesized neonates had impaired TLR activation in response to IAV. However, translational studies with human neonatal monocytes stimulated with IAV exhibited comparable IL-6 production, and sustained TLR2 expression compared to adults. Next, to further investigate the role of TLR2, transgenic mice lacking the TLR2 gene (TLR2-/-) were intranasally infected with IAV. TLR2-/- neonates displayed improved survival over C57BL/6 neonates after IAV infection, with reduced neutrophil recruitment at 6-days post-infection. To test the role of neutrophils in increasing mortality, neutrophil depletion was performed in C57BL/6 neonates; survival was improved. Additionally, treatment with an anti-TLR2 blocking antibody improved survival in the C57BL/6 neonates. Similarly, myeloid-specific TLR2-deficient mice demonstrated enhanced survival with improved histopathology and decreased neutrophil-associated pro-inflammatory cytokines and chemokines (IL-6, TNF-α, MCP-1, CXCL1), despite no changes in immune cell recruitment. Moreover, conditional knockout neonates did not amplify production of pro-inflammatory cytokines and chemokines from 3-days post-infection to 6-days post-infection, compared to the age-matched neonatal control group. These findings suggest that myeloid TLR2 signaling exacerbates neonatal susceptibility to respiratory viral infections by driving increased pulmonary inflammation over the first week of infection. Targeting TLR2 could represent a therapeutic strategy to protect this vulnerable population during respiratory viral infections.
- Open Access
Age Matters: Key Contributors to Interferon Toxicity in Infants During Influenza Virus Infection
Respiratory viral infections are a leading cause of early childhood hospitalizations in the United States. Neonatal immune responses are reliant on innate mechanisms during the first few months of life. Interferons (IFNs) are a key component of this response. These antiviral cytokines are produced early in infection and aid in viral control and clearance. Although generally considered protective in the setting of respiratory viral infections, the recent literature has suggested that IFNs may exacerbate disease. In the process of promoting an antiviral environment, IFNs impede cell proliferation, contribute to pulmonary barrier disruption, and generate reactive oxygen species. This is not tolerated in the rapidly developing neonatal lung. Therefore, IFNs contribute to pathogenesis in the influenza-infected neonate. This review focuses on the potential mechanisms that drive IFN-induced toxicity in neonates and prospective therapeutics to mitigate this toxicity.
Open AccessAge Matters: Key Contributors to Interferon Toxicity in Infants During Influenza Virus Infection
Respiratory viral infections are a leading cause of early childhood hospitalizations in the United States. Neonatal immune responses are reliant on innate mechanisms during the first few months of life. Interferons (IFNs) are a key component of this response. These antiviral cytokines are produced early in infection and aid in viral control and clearance. Although generally considered protective in the setting of respiratory viral infections, the recent literature has suggested that IFNs may exacerbate disease. In the process of promoting an antiviral environment, IFNs impede cell proliferation, contribute to pulmonary barrier disruption, and generate reactive oxygen species. This is not tolerated in the rapidly developing neonatal lung. Therefore, IFNs contribute to pathogenesis in the influenza-infected neonate. This review focuses on the potential mechanisms that drive IFN-induced toxicity in neonates and prospective therapeutics to mitigate this toxicity.
- 18 March 2025
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 214 (5) , 1022-1031
Cathelicidin-related antimicrobial peptide (CRAMP) is toxic during neonatal murine influenza virus infection
Respiratory viral infections are a major contributor to mortality in children under 5 years of age, and disproportionately affect preterm neonates. Previously, using our established 3-day-old neonatal murine model of influenza virus infection, we demonstrated that treatment of neonatal mice with intranasal Lactobacillus rhamnosus GG (LGG) prior to influenza viral infection improved survival. Transcriptional analysis revealed expression of the mouse cathelicidin-related antimicrobial peptide (CRAMP, encoded by CRAMP) was downregulated in LGG-treated neonates. Mouse CRAMP is a key effector protein secreted by infected epithelial cells and resident and infiltrating immune cells, but the role of CRAMP in neonatal defense to respiratory viruses is unknown. Neonatal mice with a deleted CRAMP gene (CRAMP–/–) were intranasally infected with influenza virus. CRAMP–/– neonates had improved survival over C57BL/6 neonates after influenza viral infection (75% vs. 14%, p < 0.05). Next, immune cell recruitment to the lung of infected neonates was determined. Surprisingly, at 3-days postinfection, there was increased recruitment of neutrophils, inflammatory monocytes, and alveolar macrophages, coupled with increased proinflammatory cytokine and chemokine production in CRAMP–/– compared to C57BL/6 neonates. However, this changed over the first week of infection. C57BL/6 neonatal mice increased CRAMP production significantly, in direct contrast to their adult counterparts. Inflammatory cytokine production increased that indicated CRAMP amplified the innate immune response later in the infection. Furthermore, we identified pulmonary nonimmune cells as an important source of increased CRAMP levels as the infection progressed and CRAMP production drove mortality. These insights emphasize the age-specific role of CRAMP in influenza viral pathogenesis.
- 18 March 2025
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 214 (5) , 1022-1031
Cathelicidin-related antimicrobial peptide (CRAMP) is toxic during neonatal murine influenza virus infection
Respiratory viral infections are a major contributor to mortality in children under 5 years of age, and disproportionately affect preterm neonates. Previously, using our established 3-day-old neonatal murine model of influenza virus infection, we demonstrated that treatment of neonatal mice with intranasal Lactobacillus rhamnosus GG (LGG) prior to influenza viral infection improved survival. Transcriptional analysis revealed expression of the mouse cathelicidin-related antimicrobial peptide (CRAMP, encoded by CRAMP) was downregulated in LGG-treated neonates. Mouse CRAMP is a key effector protein secreted by infected epithelial cells and resident and infiltrating immune cells, but the role of CRAMP in neonatal defense to respiratory viruses is unknown. Neonatal mice with a deleted CRAMP gene (CRAMP–/–) were intranasally infected with influenza virus. CRAMP–/– neonates had improved survival over C57BL/6 neonates after influenza viral infection (75% vs. 14%, p < 0.05). Next, immune cell recruitment to the lung of infected neonates was determined. Surprisingly, at 3-days postinfection, there was increased recruitment of neutrophils, inflammatory monocytes, and alveolar macrophages, coupled with increased proinflammatory cytokine and chemokine production in CRAMP–/– compared to C57BL/6 neonates. However, this changed over the first week of infection. C57BL/6 neonatal mice increased CRAMP production significantly, in direct contrast to their adult counterparts. Inflammatory cytokine production increased that indicated CRAMP amplified the innate immune response later in the infection. Furthermore, we identified pulmonary nonimmune cells as an important source of increased CRAMP levels as the infection progressed and CRAMP production drove mortality. These insights emphasize the age-specific role of CRAMP in influenza viral pathogenesis.
- Open Access
- 19 February 2025
- Published by Elsevier in Mucosal Immunology
- Vol. 18 (3) , 607-619
Influenza virus-induced type I interferons disrupt alveolar epithelial repair and tight junction integrity in the developing lung
- 19 February 2025
- Published by Elsevier in Mucosal Immunology
- Vol. 18 (3) , 607-619
Open AccessInfluenza virus-induced type I interferons disrupt alveolar epithelial repair and tight junction integrity in the developing lung
- 5 September 2024
- Published by Drexel University Libraries
Role of IDO1 in the spiral artery remodeling during pregnancy
During gestation, the trophoectoderm, the outer layer of the blastocyst, engages with the uterine wall to form the placenta, a temporary organ at the maternal-fetal vascular interface. To increase blood flow through the placenta, uterine spiral arteries transform into large, dilated, low-resistance vessels in which the endothelial layer has been replaced by infiltrating extravillous trophoblasts that invade the uterine myometrium. While it has been widely assumed that these invasive trophoblasts drive the spiral artery remodeling (SAR) process, careful temporal analysis has established that SAR initiation occurs prior to trophoblast arrival. Rather, it is decidual immune cells that are implicated in causing the disorganization of vascular cells and separation of smooth muscle layers characteristic of early-stage SAR. Mouse studies have shown that uterine natural killer (uNK) cells, which expand rapidly in the decidua at mid-gestation, are required for SAR to proceed normally and that this activity is dependent on the inflammatory cytokine interferon-gamma (IFNγ). It therefore has been clearly established that inflammation plays a fundamental role in this complex, physiological process, but thus far a detailed understanding of the specific factors involved downstream of IFNγ has remained elusive. Addressing the unresolved role of inflammation in the reshaping the vasculature at this key stage of gestation has been the core focus of my research project. To better understand how the inflammatory microenvironment established by decidual immune cells promotes SAR, it is important to have an assay that quantifiably assesses the remodeling process. To this end, I describe the development of a method whereby sections of mid-gestation mouse embryos are prepared for comparative assessment of SAR initiation based on confocal microscopy-based immunofluorescence quantification of staining for smooth muscle alpha actin (SMA) within individual arterial vessels (Chapter 1). This technique provides a reproducible and objectively quantifiable methodology for monitoring this initial stage of the SAR process for any perturbations that might result from modifications to the inflammatory microenvironment. Trophoblasts must next migrate to the spiral arteries for SAR to proceed, and I further describe the use methods for assessing trophoblast invasiveness as a later aspect of the SAR process using both in vitro human cell and in vivo mouse-based experimental models (Chapter 2). The tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO1) is an IFNγ- inducible protein that is highly expressed in the placenta at mid-gestation. Through its well-established capacity to promote T cell tolerance, IDO1 has gained widespread recognition as a mechanism for protecting hemi-allogeneic fetus from maternal immunity. More recently, our laboratory has determined that a specific myeloid subpopulation that protects neovasculature from IFNγ due to IDO1 mediated activation of the integrated stress response through general control non-derepressible 2 (GCN2) that results in elevated production of interleukin 6 (IL6). Research studies have reported that IDO1 deficiency can induce symptoms akin to preeclampsia in both mice and humans. While these findings suggest a role of IDO1 in decidual vascularization during pregnancy, this has yet to be explored. Altered expression of IL6 and its receptor in decidua have likewise been reported in cases of sporadic miscarriage and in vitro assays have identified IL6 as a potential factor driving trophoblast invasion. Based on our findings in settings of pathological neovascularization, I have investigated the hypothesis that the initiation of SAR similarly runs through IFNγ/IDO1/IL6. In line with previous reports, vessel wall SMA remained significantly elevated in mice lacking IFNγ, and consistent with our hypothesis lack of either IDO1 or GCN2 resulted in a similar retention of SMA. However, in contrast to IDO1 or GCN2 deficiency which only partially attenuated SMA loss, IL6 deficiency blocked SMA loss almost completely, suggesting that IDO1 is not the sole input driving IL6 in this context. IFNγ expression was unaffected in mice lacking IDO1, GCN2 or IL6 despite the defects in vessel wall remodeling observed in these mice while IL6 expression was impaired in mice lacking IFNγ, IDO1 or GCN2 consistent with IFNγ being an upstream driver and IL6 a downstream effector in the SAR process. In addition to these effects on the vessel wall, IL6 was confirmed to promote trophoblast migration in vitro and loss of IFNγ, IDO1, GCN2 or IL6 all compromised trophoblast invasiveness in vivo. Thus, two key features of the SAR process, vessel wall remodeling and trophoblast invasion are subject to control by this inflammatory pathway. These data provide important elucidation of mechanism by which inflammation controls SAR an suggest potential pathways for interventional therapy to mitigate the effects when this process goes awry.
- 5 September 2024
- Published by Drexel University Libraries
Role of IDO1 in the spiral artery remodeling during pregnancy
During gestation, the trophoectoderm, the outer layer of the blastocyst, engages with the uterine wall to form the placenta, a temporary organ at the maternal-fetal vascular interface. To increase blood flow through the placenta, uterine spiral arteries transform into large, dilated, low-resistance vessels in which the endothelial layer has been replaced by infiltrating extravillous trophoblasts that invade the uterine myometrium. While it has been widely assumed that these invasive trophoblasts drive the spiral artery remodeling (SAR) process, careful temporal analysis has established that SAR initiation occurs prior to trophoblast arrival. Rather, it is decidual immune cells that are implicated in causing the disorganization of vascular cells and separation of smooth muscle layers characteristic of early-stage SAR. Mouse studies have shown that uterine natural killer (uNK) cells, which expand rapidly in the decidua at mid-gestation, are required for SAR to proceed normally and that this activity is dependent on the inflammatory cytokine interferon-gamma (IFNγ). It therefore has been clearly established that inflammation plays a fundamental role in this complex, physiological process, but thus far a detailed understanding of the specific factors involved downstream of IFNγ has remained elusive. Addressing the unresolved role of inflammation in the reshaping the vasculature at this key stage of gestation has been the core focus of my research project. To better understand how the inflammatory microenvironment established by decidual immune cells promotes SAR, it is important to have an assay that quantifiably assesses the remodeling process. To this end, I describe the development of a method whereby sections of mid-gestation mouse embryos are prepared for comparative assessment of SAR initiation based on confocal microscopy-based immunofluorescence quantification of staining for smooth muscle alpha actin (SMA) within individual arterial vessels (Chapter 1). This technique provides a reproducible and objectively quantifiable methodology for monitoring this initial stage of the SAR process for any perturbations that might result from modifications to the inflammatory microenvironment. Trophoblasts must next migrate to the spiral arteries for SAR to proceed, and I further describe the use methods for assessing trophoblast invasiveness as a later aspect of the SAR process using both in vitro human cell and in vivo mouse-based experimental models (Chapter 2). The tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO1) is an IFNγ- inducible protein that is highly expressed in the placenta at mid-gestation. Through its well-established capacity to promote T cell tolerance, IDO1 has gained widespread recognition as a mechanism for protecting hemi-allogeneic fetus from maternal immunity. More recently, our laboratory has determined that a specific myeloid subpopulation that protects neovasculature from IFNγ due to IDO1 mediated activation of the integrated stress response through general control non-derepressible 2 (GCN2) that results in elevated production of interleukin 6 (IL6). Research studies have reported that IDO1 deficiency can induce symptoms akin to preeclampsia in both mice and humans. While these findings suggest a role of IDO1 in decidual vascularization during pregnancy, this has yet to be explored. Altered expression of IL6 and its receptor in decidua have likewise been reported in cases of sporadic miscarriage and in vitro assays have identified IL6 as a potential factor driving trophoblast invasion. Based on our findings in settings of pathological neovascularization, I have investigated the hypothesis that the initiation of SAR similarly runs through IFNγ/IDO1/IL6. In line with previous reports, vessel wall SMA remained significantly elevated in mice lacking IFNγ, and consistent with our hypothesis lack of either IDO1 or GCN2 resulted in a similar retention of SMA. However, in contrast to IDO1 or GCN2 deficiency which only partially attenuated SMA loss, IL6 deficiency blocked SMA loss almost completely, suggesting that IDO1 is not the sole input driving IL6 in this context. IFNγ expression was unaffected in mice lacking IDO1, GCN2 or IL6 despite the defects in vessel wall remodeling observed in these mice while IL6 expression was impaired in mice lacking IFNγ, IDO1 or GCN2 consistent with IFNγ being an upstream driver and IL6 a downstream effector in the SAR process. In addition to these effects on the vessel wall, IL6 was confirmed to promote trophoblast migration in vitro and loss of IFNγ, IDO1, GCN2 or IL6 all compromised trophoblast invasiveness in vivo. Thus, two key features of the SAR process, vessel wall remodeling and trophoblast invasion are subject to control by this inflammatory pathway. These data provide important elucidation of mechanism by which inflammation controls SAR an suggest potential pathways for interventional therapy to mitigate the effects when this process goes awry.
- 19 April 2024
- Published by Drexel University Libraries
Development of a high throughput high content imaging viral titer assay to investigate the effect of substance misuse on HIV-1 replicative dynamics in hMDMs
Over 38 million people are infected with HIV-1 worldwide and in the past four decades of the HIV-1 pandemic there have been numerous failures and successes. Most notably, the successful development of antiretroviral therapies has contributed greatly to the increased longevity of people living with HIV-1 (PLWH). However, with antiretroviral control, the counterbalance is that HIV-1 is a chronic infection, latently infecting reservoirs, and inflammation over long periods of time that lead to HIV-associated comorbidities affecting entire body systems such as the central nervous system, cardiovascular, respiratory, and gastrointestinal systems. Modeling how HIV-1 interacts in the cellular niches of these reservoirs is an essential part of unraveling the underlying mechanisms associated with the development of disease and exacerbation of clinical HIV-1 presentation. We discuss the historical perspectives of HIV-1, summarizing the four-decade long pandemic, HIV-1 biology, and the epidemiological burden of substance misuse as a rationale for investigating HIV-1 viral dynamics. To aid in our investigations of viral dynamics, we have developed a novel high throughput and rapid high content imaging viral titer assay that aims to assess viral maturation and in combination with other infection kinetic studies can reveal the efficiency of viral replication and how that may change in different co-morbid conditions such as substance misuse. Our data demonstrate that we can reliably assess viral titer, and by extension viral maturation in viral stocks, and experimental in vitro models of the substance misuse downstream effect of dopamine exposure, which supports previous published work. We also demonstrate preliminary findings that suggest cocaine has the capability to also exacerbate HIV-1 infection in the absence of dopamine in primary hMDMs. These studies and future work will allow for more precise interrogation of HIV-1 viral dynamics that underscore undefined mechanisms of viral replication, spread, and disease progression in cellular and tissue reservoirs.
- 19 April 2024
- Published by Drexel University Libraries
Development of a high throughput high content imaging viral titer assay to investigate the effect of substance misuse on HIV-1 replicative dynamics in hMDMs
Over 38 million people are infected with HIV-1 worldwide and in the past four decades of the HIV-1 pandemic there have been numerous failures and successes. Most notably, the successful development of antiretroviral therapies has contributed greatly to the increased longevity of people living with HIV-1 (PLWH). However, with antiretroviral control, the counterbalance is that HIV-1 is a chronic infection, latently infecting reservoirs, and inflammation over long periods of time that lead to HIV-associated comorbidities affecting entire body systems such as the central nervous system, cardiovascular, respiratory, and gastrointestinal systems. Modeling how HIV-1 interacts in the cellular niches of these reservoirs is an essential part of unraveling the underlying mechanisms associated with the development of disease and exacerbation of clinical HIV-1 presentation. We discuss the historical perspectives of HIV-1, summarizing the four-decade long pandemic, HIV-1 biology, and the epidemiological burden of substance misuse as a rationale for investigating HIV-1 viral dynamics. To aid in our investigations of viral dynamics, we have developed a novel high throughput and rapid high content imaging viral titer assay that aims to assess viral maturation and in combination with other infection kinetic studies can reveal the efficiency of viral replication and how that may change in different co-morbid conditions such as substance misuse. Our data demonstrate that we can reliably assess viral titer, and by extension viral maturation in viral stocks, and experimental in vitro models of the substance misuse downstream effect of dopamine exposure, which supports previous published work. We also demonstrate preliminary findings that suggest cocaine has the capability to also exacerbate HIV-1 infection in the absence of dopamine in primary hMDMs. These studies and future work will allow for more precise interrogation of HIV-1 viral dynamics that underscore undefined mechanisms of viral replication, spread, and disease progression in cellular and tissue reservoirs.
- 29 March 2024
- Published by Drexel University Libraries
Glycosylation of immunoglobulins
Glycoproteins are post-translationally modified proteins containing branched sugar structures referred to as glycans. One major class of glycoproteins are the immunoglobulins. Immunoglobulins play a key role in the adaptive immune response and require glycosylation in the Golgi apparatus before release into circulation. The size, charge, and shape of glycans added to immunoglobulins determine half-life, effector function, and Fc receptor binding affinity. In the laboratory, classes of immunoglobulins can be isolated from patient blood and analyzed for glycan content using lectin, chromatographic, and mass spectrometry methods. In this thesis, glycans from human IgG and IgM are analyzed for changes during health and disease states. We elected to study Lyme disease because the host response to Lyme disease had not been characterized using a glycomic approach. We hypothesized that the host antibody glycomic response to acute Lyme disease would reveal more information about how the host immune response is mounted. Further, we hypothesized that this study could reveal mechanisms of host adaptive immune system evasion by the Lyme disease bacterium. We first asked: what immunoglobulin glycan alterations are associated with acute Lyme disease infection in humans? Here, we demonstrate IgG and IgM glycans produced in response to acute Lyme disease contain elevated levels of galactose and sialic acid. Next, we link the changes in immunoglobulin glycan profiles observed during acute Lyme disease to the functional impairment of IgG to signal for antibody-dependent cellular cytotoxicity. Following antibiotic therapy for Lyme disease, we demonstrate antibody glycosylation decreased the sialic acid content to reflect the resolution of Lyme disease. Later in this thesis, we characterize the glycan-associated serological response to COVID-19 by studying hospitalized patients infected from the Immunophenotyping assessment in a COVID-19 cohort. Studies of the COVID-19 glycomic response were previously limited to IgG glycans. We sought to characterize the glycomic response of both IgG and IgM to gain more insight into the adaptive immune response during COVID-19. We hypothesized that glycans on IgM would stratify patients with nonsevere versus severe COVID-19 better than IgG glycans. Further, we hypothesized that IgM glycans characterization would provide more insight into the acute host response to the viral infection. Here, we report significant differences in the IgG and IgM glycan profiles - particularly the ability of IgM glycans to aid in the stratification of nonsevere versus severe COVID-19 patients. We next hypothesized that the IgM glycans were modulating IgM- directed complement deposition. To test this, we developed an antigen-specific assay using purified IgM with and without sialidase digestions. Using this assay, we demonstrate a potential mechanism of the sialic acid glycans on IgM to promote complement deposition in severely infected COVID-19 patients. In conclusion, this thesis examines immunoglobulin glycosylation during human adaptive immune responses and links these glycan changes to modulated immunoglobulin effector function. In the case of acute Lyme disease, the sialic acid on antigen-specific IgG responding to Lyme disease impairs the induction of ADCC signaling. This impairment could be one mechanism of host immune evasion benefiting the Lyme disease bacterium. In contrast, elevated levels of sialic acid on IgM isolated from severe COVID-19 infections were associated with increased rates of complement deposition. Our data suggest this elevated IgM sialic acid could promote acute respiratory distress due to elevated complement deposition in the lung epithelia and endothelia of severe COVID-19 patients. Future studies should determine which pathways and cytokines are responsible for shifting the glycosylation of IgG and IgM during acute immune responses.
- 29 March 2024
- Published by Drexel University Libraries
Glycosylation of immunoglobulins
Glycoproteins are post-translationally modified proteins containing branched sugar structures referred to as glycans. One major class of glycoproteins are the immunoglobulins. Immunoglobulins play a key role in the adaptive immune response and require glycosylation in the Golgi apparatus before release into circulation. The size, charge, and shape of glycans added to immunoglobulins determine half-life, effector function, and Fc receptor binding affinity. In the laboratory, classes of immunoglobulins can be isolated from patient blood and analyzed for glycan content using lectin, chromatographic, and mass spectrometry methods. In this thesis, glycans from human IgG and IgM are analyzed for changes during health and disease states. We elected to study Lyme disease because the host response to Lyme disease had not been characterized using a glycomic approach. We hypothesized that the host antibody glycomic response to acute Lyme disease would reveal more information about how the host immune response is mounted. Further, we hypothesized that this study could reveal mechanisms of host adaptive immune system evasion by the Lyme disease bacterium. We first asked: what immunoglobulin glycan alterations are associated with acute Lyme disease infection in humans? Here, we demonstrate IgG and IgM glycans produced in response to acute Lyme disease contain elevated levels of galactose and sialic acid. Next, we link the changes in immunoglobulin glycan profiles observed during acute Lyme disease to the functional impairment of IgG to signal for antibody-dependent cellular cytotoxicity. Following antibiotic therapy for Lyme disease, we demonstrate antibody glycosylation decreased the sialic acid content to reflect the resolution of Lyme disease. Later in this thesis, we characterize the glycan-associated serological response to COVID-19 by studying hospitalized patients infected from the Immunophenotyping assessment in a COVID-19 cohort. Studies of the COVID-19 glycomic response were previously limited to IgG glycans. We sought to characterize the glycomic response of both IgG and IgM to gain more insight into the adaptive immune response during COVID-19. We hypothesized that glycans on IgM would stratify patients with nonsevere versus severe COVID-19 better than IgG glycans. Further, we hypothesized that IgM glycans characterization would provide more insight into the acute host response to the viral infection. Here, we report significant differences in the IgG and IgM glycan profiles - particularly the ability of IgM glycans to aid in the stratification of nonsevere versus severe COVID-19 patients. We next hypothesized that the IgM glycans were modulating IgM- directed complement deposition. To test this, we developed an antigen-specific assay using purified IgM with and without sialidase digestions. Using this assay, we demonstrate a potential mechanism of the sialic acid glycans on IgM to promote complement deposition in severely infected COVID-19 patients. In conclusion, this thesis examines immunoglobulin glycosylation during human adaptive immune responses and links these glycan changes to modulated immunoglobulin effector function. In the case of acute Lyme disease, the sialic acid on antigen-specific IgG responding to Lyme disease impairs the induction of ADCC signaling. This impairment could be one mechanism of host immune evasion benefiting the Lyme disease bacterium. In contrast, elevated levels of sialic acid on IgM isolated from severe COVID-19 infections were associated with increased rates of complement deposition. Our data suggest this elevated IgM sialic acid could promote acute respiratory distress due to elevated complement deposition in the lung epithelia and endothelia of severe COVID-19 patients. Future studies should determine which pathways and cytokines are responsible for shifting the glycosylation of IgG and IgM during acute immune responses.
- 18 January 2023
- Published by Drexel University Libraries
Altered Innate Immune Response to Influenza Virus Infection in the Neonate
Respiratory viral infections contribute substantially to global infant mortality and disproportionately affect preterm neonates. This mortality is often attributed to the immunological immaturity of the newborn. Newborn immune responses are qualitatively and quantitatively distinct from those of adults. Neonates are ineligible for current influenza vaccines as they fail to develop effective antibody responses. Therefore, there is a critical need for developing antiviral therapeutic interventions for this extremely vulnerable population. Using our clinically relevant neonatal murine model of influenza virus infection, neonates exhibit high mortality and viral load early in influenza infection coupled with delayed innate immune transcriptional responses in the lung compared to adults. Administration of a probiotic, Lactobacillus rhamnosus GG (LGG), serves as an effective immune modulator during influenza viral infection, which improves neonatal mouse survival by calibrating innate antiviral responses, specifically type I interferons (IFN I). Uncontrolled production of IFN I, which controls viral replication, may also result in the production of pathogenic reactive oxygen species (ROS). Infants are particularly susceptible to ROS because of decreased production of antioxidants, such as superoxide dismutase 3 (SOD3). Furthermore, neonates demonstrate increased pathology under oxidative stress conditions. Neonatal infected lung epithelial cells and immune cells have an increased production of ROS in response to IFN I. The recruitment of the most potent ROS-producing immune cell, the neutrophil, is controlled by neonatal TLR 2 and ablation of this receptor or treatment with an antioxidant improves survival in neonates. Our research identifies modifiable risk factors which can be used to develop antiviral therapeutics in this currently understudied population.
- 18 January 2023
- Published by Drexel University Libraries
Altered Innate Immune Response to Influenza Virus Infection in the Neonate
Respiratory viral infections contribute substantially to global infant mortality and disproportionately affect preterm neonates. This mortality is often attributed to the immunological immaturity of the newborn. Newborn immune responses are qualitatively and quantitatively distinct from those of adults. Neonates are ineligible for current influenza vaccines as they fail to develop effective antibody responses. Therefore, there is a critical need for developing antiviral therapeutic interventions for this extremely vulnerable population. Using our clinically relevant neonatal murine model of influenza virus infection, neonates exhibit high mortality and viral load early in influenza infection coupled with delayed innate immune transcriptional responses in the lung compared to adults. Administration of a probiotic, Lactobacillus rhamnosus GG (LGG), serves as an effective immune modulator during influenza viral infection, which improves neonatal mouse survival by calibrating innate antiviral responses, specifically type I interferons (IFN I). Uncontrolled production of IFN I, which controls viral replication, may also result in the production of pathogenic reactive oxygen species (ROS). Infants are particularly susceptible to ROS because of decreased production of antioxidants, such as superoxide dismutase 3 (SOD3). Furthermore, neonates demonstrate increased pathology under oxidative stress conditions. Neonatal infected lung epithelial cells and immune cells have an increased production of ROS in response to IFN I. The recruitment of the most potent ROS-producing immune cell, the neutrophil, is controlled by neonatal TLR 2 and ablation of this receptor or treatment with an antioxidant improves survival in neonates. Our research identifies modifiable risk factors which can be used to develop antiviral therapeutics in this currently understudied population.
- 9 November 2022
- Published by Elsevier in Mucosal Immunology
- Vol. 15 (6) , 1309-1320
Severity of neonatal influenza infection is driven by type I interferon and oxidative stress
- 9 November 2022
- Published by Elsevier in Mucosal Immunology
- Vol. 15 (6) , 1309-1320
Severity of neonatal influenza infection is driven by type I interferon and oxidative stress